NICE Appraisal of Ruxolitinib for treating PV

Recently the National Institute for Health and Care Excellence (NICE) completed their appraisal of Ruxolitinib (Jakavi) for the treatment of Polycythaemia Vera (PV).  MPN Voice contributed to the process with a written submission and we were strongly represented at the committee meeting by a PV patient who has benefitted from the treatment.  However, NICE have decided that, as things stand, the drug does not represent sufficient value for money to be made available to NHS patients in England and Wales.  Despite this disappointing news, we are very grateful to the volunteers who represented the MPN community throughout the appraisal process and we hope that ultimately there will be a positive outcome for PV patients in England and Wales.